Molecular profiling of melanoma tumours explains differences in survival after T cell therapy
The more times metastasised melanoma has mutated and the patient's immune system has been activated against the tumour – the better the chances of survival after immunotherapy. This is what emerges from a research collaboration ...
Nov 28, 2017